8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic

criteria) were available for 13 OC patients; 4 had a partial response (PR), 8 had stable disease (SD), and 1 had progressive disease (PD). All responses were observed in OC patients with p53-mutated tumors. Median PFS has not yet been reached. Conclusions: AMG 900 had a manageable toxicity profile with G-CSF support and promising single-agent activity in heavily pretreated patients with taxane-resistant OC. Activity was also seen in TNBC and endometrial carcinoma (seen in escalation phase). Combination studies are planned in these tumor types. Updated data will be presented at the meeting.